Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic

Abstract

The rapid growth of 2019 novel coronavirus (COVID-19) outbreak in Wuhan, China, at the early December 2019. COVID-19 spread all over the word just a few months. The outbreak of COVID-19 infection poses major threat to international health and economy. World Health Organization (WHO) announced that the new coronavirus was an international public health emergency on January 30, 2020. However, with the spread of COVID-19, the routine medical care of lung cancer patients was affected. Because lung cancer patients have low immunity after anti-tumor treatment, they should become the main targets for epidemic prevention. Lung cancer patients are increasingly concerned about the prevention of COVID-19. It is necessary to provide individualized medical treatment and management for lung cancer patients based on patients’ conditions and regional epidemic patterns.

Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis

“…Patients with cancer, especially lung cancer, form a large group that deserves special attention. [9] Lung cancer is the second most common type of cancer, with approximately 1.8 million deaths and 2.2 million new cases in 2020. [10] Angiotensin-converting enzyme 2 (ACE2), as the only experimentally confirmed SARS-CoV-2 receptor, can facilitate the entry of viruses into cells, and its expression level is considered to be a marker of susceptibility to COVID-19.…”

“…In addition, the detection of COVID-19 on the imaging of lung cancer patients is atypical due to the influence of the tumor. Therefore, it becomes increasingly difficult to identify and diagnose COVID-19 pneumonia early in lung cancer patients [9] .…”

In silico prediction of COVID-19 cytokine storm in lung cancer types

“…In December 2019, a cluster of pneumonia cases was reported in people exposed to a seafood market in Wuhan, China. The medical investigation led to the emergence of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which subsequently rapidly spread all over the world; therefore, this disease was declared as a pandemic disease by World Health Organization (WHO) in March 2020 [ 1 ]. This pandemic's critical and devastating feature is not only limited to the discovery of new viruses but also diversifying and hyperinflammatory unpredictable immune response.…”

Cancer du poumon à l’ère du COVID-19

“…Une abondante littérature a été développée très rapidement en quelques semaines sur les différents aspects de la prise en charge du cancer du poumon au moment où sévit la pandémie liée au coronavirus 19 [ [1] , [2] , [3] , [4] , [5] , [6] , [7] ]. Nous abordons dans cet article l’épidémiologie de l’épidémie Covid chez les patients atteints de cancer du poumon et les recommandations pour la prise en charge de ces patients en période d’épidémie Covid.…”